



November 06, 2025

The Manager (CRD) The BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai- 400001 Scrip Code: 530117	The Manager – Listing Department National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai - 400 051 Symbol: PRIVISCL
--	--

Dear Sir / Madam,

Sub: Investors Presentation – Financial & Operation Review for quarter and half year ended
September 30, 2025

Pursuant to our letter dated October 31, 2025, intimating about Earnings Conference Call to be held on Friday, November 07, 2025, at 04:00 pm IST and regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we also enclose herewith the Investors Presentation on Financial & Operational Review for the quarter, and half year ended September 30, 2025.

The Investors' Presentation is also being uploaded on the Company's website www.privi.com.

You are requested to kindly take the same on record.

Thanking you,

Yours Sincerely,

For **Privi Speciality Chemicals Limited**

Ashwini Saumil Shah
Company Secretary



Encl: Investors Presentation





PRIVI SPECIALITY CHEMICALS LIMITED

Knowledge Centre & Regd. Office : Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privi.com | CIN: L15140MH1985PLC286828



Privi Speciality Chemicals Limited

Investor Presentation – Q2 & H1 FY26





Safe Harbor



This presentation and the accompanying slides (the “Presentation”), which have been prepared by Privi Speciality Chemicals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



All-Time High Quarterly and Half-Yearly Results

Q2FY26

Revenue

Rs. 678.82 Crs  **26%**
YoY

EBITDA

Rs. 182.14 Crs  **59%**
YoY

EBITDA Margin

26.83%  **549**
bps

PAT

Rs. 90.21 Crs  **101%**
YoY

H1FY26

Rs. 1,246.08 Crs  **24%**
YoY

Rs. 323.19 Crs  **53%**
YoY

25.94%  **485**
bps

Rs. 147.76 Crs  **94%**
YoY



Key Business Highlights



Record-breaking Q2 & H1FY26 performance.



Continued growth in flagship products – higher volumes and marginal increase in selling prices



Higher EBITDA margins driven by the company's ongoing focus on operational excellence and growing contribution from value added products, and receipt of state incentives.



Part of Phase I of the expansion has been completed before time providing the impetus for higher volumes, balance expansion is on track and expected to be completed by Dec-25



Phase II of the Multispecialty aroma chemicals project is also on track



Improved working capital management has led to a steady improvement in return ratios



Implementation of Company's 5k:1k vision is on track to be realized over the next 3-4 years




Company conferred with 1st prize at the IFEAT 2025 conference held in Sweden, for Sustainability practice.




Consistent Performance over last 10 Quarters




Revenue Trend (Rs. In Cr)




EBITDA Trend (Rs. In Cr)



EBITDA Margin Trend



PAT Trend (Rs. In Cr)





From the CMD's Desk



We are pleased to inform that the Company has delivered its best-ever quarterly and half yearly performance, registering a 26% and 24% revenue growth on a YoY basis. Over the last ten quarters, our performance has consistently improved, driven by robust demand, operational efficiencies, and an enhanced product mix, resulting in EBITDA margins sustaining above 20%.

We have outlined a three-phase expansion roadmap over the next 3–4 years positioning the company for its next phase of growth. These initiatives are aimed at enhancing capacity by ~50%, expanding our specialty products portfolio, and strengthening scalability.

In line with our belief that *“What a mind perceives, man achieves,”* we have taken a decisive step toward operational consolidation through the proposed Scheme of Amalgamation of Privi Fine Sciences Private Limited, Privi Biotechnology Private Limited, and Privi Speciality Chemicals Limited. This move is aimed at unlocking synergies, enhancing efficiencies, and creating a unified structure that supports scalable growth, innovation, and deeper customer engagement across the value chain.

As we look ahead, our strategic priorities remain clear — to continue building a world-class aroma chemicals company that leads with purpose, delivers with precision, and grows responsibly.

We thank all our stakeholders for their continued trust and support as we embark on this next phase of transformative growth.



Mr. Mahesh Babani
Chairman & Managing Director

Consolidated Profit & Loss Account

Particulars (Rs. Crores)	Q2 FY26	Q2 FY25	YoY	H1FY26	H1FY25	YoY
Revenue from Operations	678.71	532.79		1,237.53	996.77	
Other Income	0.11	4.47		8.55	7.17	
Total Income	678.82	537.27	26%	1,246.08	1,003.94	24%
Cost of materials consumed	334.32	292.30		609.56	552.91	
Employee Expenses	29.02	20.83		56.41	40.99	
Power & Fuel	45.49	41.13		84.38	76.10	
Other Expenses	87.85	68.35		172.54	122.21	
EBITDA	182.14	114.66	59%	323.19	211.74	53%
EBITDA Margin (%)	26.83%	21.34%		25.94%	21.09%	
Depreciation	35.60	32.37		71.81	64.50	
EBIT	146.54	82.30		251.39	147.24	
Finance Cost	21.47	21.54		45.14	43.56	
Profit before Tax	125.07	60.75		206.25	103.68	
Tax	34.86	15.91		58.49	27.38	
Profit After Tax	90.21	44.84	101%	147.76	76.30	94%
PAT Margin (%)	13.29%	8.35%		11.86%	7.60%	
EPS	24.04	11.43		39.90	19.46	



Consolidated Balance Sheet

Assets (Rs. Crores)	Sept-25	Mar-25	Liabilities (Rs. Crores)	Sept-25	Mar-25
Non Current assets			Equity		
Property, Plant and Equipment	1,036.77	1,097.89	Equity Share capital	39.06	39.06
Capital work-in-progress	262.03	127.47	Other Equity	1,200.92	1,064.37
Intangible Assets	8.54	10.64	Non-Controlling Interest	6.41	14.49
Intangible Assets under development	13.87	13.87	Total Equity	1,246.39	1,117.92
Right Use of Assets	53.36	47.49	Financial liabilities		
Financial Assets			Borrowings	505.57	511.13
Investments	0.87	0.83	Lease Liabilities	5.45	9.46
Loans	-	-	Provisions	28.41	24.51
Other financial assets	22.75	54.26	Deferred tax liabilities (Net)	21.86	24.11
Income Tax Assets	60.74	15.35	Total Non Current Liabilities	561.29	569.22
Other non-current assets	58.64	59.41	Financial liabilities		
Total Non Current Assets	1,517.55	1,427.21	Borrowings	550.23	611.56
Current Assets			Lease Liabilities	10.68	10.68
Inventories	863.68	788.45	Trade Payables	443.72	402.25
Financial Assets			Other financial liabilities	74.12	67.08
Investments	18.69	7.54	Provisions	4.88	2.95
Trade receivables	430.08	394.15	Other current liabilities	3.07	5.53
Cash and cash equivalents	15.91	49.76	Current tax liabilities (Net)	62.68	3.33
Bank balances other than above	0.54	0.43	Total Current Liabilities	1,149.37	1,103.37
Other financial assets	2.16	1.36	Total Equity and Liabilities	2,957.05	2,790.51
Other current assets	108.44	121.61			
Total Current Assets	1,439.49	1,363.30			
Total Assets	2,957.05	2,790.51			




Consolidated Cash Flow Statement

Particulars (Rs. Crores)	Sept-25	Sept-24
Net Profit Before Tax	206.25	103.68
Adjustments for: Non-Cash Items / Other Investment or Financial Items	121.48	116.42
Operating profit before working capital changes	327.73	220.10
Changes in working capital	-46.45	-73.68
Cash generated from Operations	281.29	146.42
Direct taxes paid (net of refund)	-46.40	-26.88
Net Cash from Operating Activities	234.89	119.54
Net Cash from Investing Activities	-133.29	-119.42
Net Cash from Financing Activities	-135.45	-7.06
Net Decrease in Cash and Cash equivalents	-33.85	-6.94
Add: Cash & Cash equivalents at the beginning of the period	49.76	23.99
Cash & Cash equivalents at the end of the period	15.91	17.07

Proposed Scheme of Amalgamation

Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Limited with Privi Speciality Chemicals Limited




Area of Business

Key Rationale

- **Diverse Product Portfolio:** PFSP includes Privial, Anethole, and Cyclamen Aldehyde used in fine and functional flavours and fragrances.
- **Green Science Advantage:** Expands offerings through sustainable chemistry solutions.
- **Innovation-Driven:** Research focused on converting corn and cob into high-value products like Furfural and its derivatives.
- **Growth Enabler:** Product and R&D capabilities expected to drive long-term business growth.

- **Biotech-Focused R&D:** PBPL, a 100% subsidiary, specializes in biotechnology-driven flavour and fragrance development.
- **Green Science Vision:** Aligns with the company's belief in sustainable, nature-like aroma chemicals.
- **Strategic Merger:** Planned integration with the parent company to strengthen core operations and enhance agility.
- **Synergistic Growth:** Merger expected to unlock faster growth through combined expertise in aroma chemicals.



We Touch Your Lives Everyday





Leading manufacturer, Supplier & Exporter of Aroma Chemicals



3+ decades of experience
in Aroma chemicals



Preferred supplier to the World's top
15 fragrance companies and World's
leading MNC & FMCG companies



Formidable **Strength**
In **Pine Chemistry**



Present across **diverse**
categories of **aroma**
chemicals



75+
Products



7
State-of-the-art manufacturing facilities



40+ Countries
Worldwide Presence



48,000 MTPA
Production capacity



36,000 MTPA
CST processing capacity



9,600 MTPA
GTO processing capacity



2 R&D centers
Dedicated R&D centres driving innovation




Strategically Located
Near JNPT Port & Ankleshwar Dry Port



70 %
Raw Materials Used are derived from Renewable
Resources



Our Journey



Privi's Sustainability Journey – From Bronze to Platinum



Highest possible certification provided by **Ecovadis** - World's most trusted sustainability rating



Top 1% globally in Environment, Labor, Ethics & Sustainable Procurement



Recognized for **Responsible chemical manufacturing**



Validated by International Clients and Supply Chains



Aligned with Global ESG benchmarks & REACH/Responsible Care



Reaffirms Privi's commitment to sustainability, compliance, and ethical supply chain leadership in the chemical sector



Core Values – 5S



Safety

Embedded across manufacturing and R&D functions

Sustainability

Reflected in financial management and product development



Sense of Urgency

Applied to market opportunities and strategic joint ventures



Super Transparency

Evident in stakeholder engagement and governance practices



Sincere Respect & Care

Central to Privi's ESG commitments



Key Recognitions



Key Certifications





Sustaining Growth with Responsibility

Sustainability KPIs

Topic	Strategic Sustainability Target
Climate	Scope 1 and 2 Reduction of 50.4 % by 2032 comparing base year of 2022
	35 % reduction of Scope 3 GHG emissions by 2034 comparing base year of 2024
	To perform Product Carbon footprint for 20 products contributing 70% of revenue
Energy	Source 50% energy from renewables by 2032.
Water	90% Recycled water use in the operations by 2030 comparing base year 2022
Waste	Achieve Zero Waste to landfill (ZWL) certification by FY 2030 for all major manufacturing facilities by 2030.
Biodiversity	To plant 1,20,000 nos of trees to increase Carbon Sink by 2028.
Sustainable Supply Chain	100% of Suppliers sign the supplier Code of Conduct
	10% Procurement from MSMEs by 2030.

Committed to the following United Nations Sustainable Development Goals





State of the Art Manufacturing Facilities Backed by In-House R&D



6 Units

Mahad, Maharashtra



Key Products

- Dihydromyrcenol
- Amber Fleur
- Pine Oil and Terpinol
- Camphor
- Speciality
- Citral
- Prionyl
- Ionone Products

1 Unit

Jhagadia, Gujarat



Key Products

- OTBCHA
- PTBCHA
- Galaxmusk
- Indomerane
- Floravone

2 R&D centres

Nerul & Mahad, Maharashtra



New Products Developed

- Camphor
- Galaxmusk
- Prionyl
- Floravone
- Indomerane
- Amber Woody Xtreme



Products Under Development

- Furfural
- Maltol
- Ethyl Maltol
- 10+ other High end Specialty Products
- 40+ Products under PRIGIV
- Cyclopentanone

Benefits of CST Backward Integration



Recycling pulp and paper waste ensures long-term supply visibility.



Prices are more stable than GTO



Long-term supply contracts with 70+ paper mills across the globe


48,000 MTPA
Production capacity

36,000 MTPA
CST processing capacity

9,600 MTPA
GTO processing capacity

Backward Integration with CST – A Key Advantage

Backward integration for captive α & β Pinenes via Crude Sulphate Turpentine (CST) route



Privi Advantage



1 of 4 companies globally to have this technology




Largest single CST processing site in the world – 36,000 TPA



CST procurement agreements with 70+ mills across EU & NA



Privi's presence across the Value Chain



Privi's basket has more than 20 products with a global market share exceeding 20%



Wide applications across F&F and FMCG with a diverse client base

Wide Applications



Fragrance

Fine Fragrance
Perfume
Air Fresheners
Incense Sticks



Home Care

Soaps
Floor and Disinfectant
Cleaner Detergent
Hand Wash



Personal Care

Shampoos
Conditioners
Lipsticks
Creams & Lotions



Others

Antiseptic Liquids
Healthcare
Pharmaceuticals
Among Others

Diverse Client Base



Serving the evolving needs of end consumers across the globe



Operational Excellence : Driving Efficiency, Quality & Sustainability




 Safety & People-First Culture	 Sustainability Integration	 Process Efficiency	 R&D and Quality	 Asset & Capacity Optimization
• Regular safety audits and emergency drills • Skilling programs & Kaizen for continuous improvement • Culture of urgency, transparency & care through the 5S Values	• About 70% raw materials from renewable sources • Energy, water, and waste reduction programs • Zero Liquid Discharge (ZLD) facilities in place • Solvent recovery, by-product valorization	• Continuous process improvement leading to better Yields • Strong cost discipline and operational controls driving profitability • Energy efficiency improvement to save utility cost	• 2 R&D centers (Mahad & Nerul) • 116-member R&D team with scientists, microbiologists, chemists • Concept-to-Commercialisation framework ensures faster time-to-market • Focus on biotechnology, synthetic innovations & green chemistry	• Capacity debottlenecking across plants • Preventive and Predictive maintenance systems in place • Capacity Expansion plan

Reliable, scalable and future-ready operations ensure quality, compliance, and prompt service




Steady Growth in Annual Performance


Total Income (Rs. In Cr)




EBITDA (Rs. In Cr)




EBITDA Margin (%)




PAT (Rs. In Cr)




Net Debt (Rs. In Cr) & Net Debt / Equity (x)




Net Debt / EBITDA (x)



Net Working Capital (No. of days)




ROCE & ROE (%)






Key Growth Levers




Evolving Lifestyles Leads to Perpetual Rising Demand




- Surge in Niche fragrance requirements
- Need for adaptive, stable, and sustainable aroma molecules
- Trend towards gender-neutral and mood-based scents
- Shift from “Mass Scenting” to “Micro-Experiences”

World Population (In Bn)



*Rising population
driving growth in
personal product
consumption*



Privi's is well positioned to meet rising home, personal & air care product demand




Demand Outlook : Trends and Features

Privi is well positioned to meet the rising demand of aroma chemicals with strong competitive advantages

Increasing Awareness and Growing End-use Segments to Drive Demand

Global Aroma Chemicals Market Size



Growth Drivers – Emerging Trends



Growing Urbanization and Lifestyle Upgrade

Rising urbanization and changing consumer lifestyles are boosting the consumption of fragrance-based products



Shift towards Sustainable Ingredients

Preference for bio-based and eco-friendly aroma chemicals is reshaping product innovation and market positioning



Sustainable & Biotech-Driven Innovation

Biotech and green chemistry enabling low-carbon, renewable aroma chemical production.



Expanding Asian & Emerging Markets

Rising affluence and premiumization driving fragrance usage in personal care and home care.

Industry Features



High R&D Intensity

Innovation-led, with constant pressure to deliver novel and safe olfactory molecules.



Complex Regulatory Ecosystem

Compliance with IFRA, REACH, and other global standards is critical for market access



Sticky Customer Relationships

Long product development cycles and high switching costs ensure recurring revenue streams



High Entry Barriers

Specialized tech, formulations, and long product development timelines protect incumbents

Thank You !

Company:



PRIVI

Privi Speciality Chemicals Ltd.

CIN – L15140MH1985PLC286828

Mr. Narayan S. Iyer – Chief Financial Officer

Email – investors@privi.co.in

www.privico.in

Investor Relations Advisor :

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Mr. Shrikant Sangani / Ms. Shaily Patwa

Email – shrikant.sangani@sgapl.net / shaily.p@sgapl.net

Mobile No – +91 9619595686 / 9819494608

www.sgapl.net

